Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?

详细信息    查看全文

• 作者：Paola Papaldo ; Serena Di Cosimo ; Gianluigi Ferretti ; Paolo Carlini ; Aless ; ra Fabi ; Fabiana Cecere ; Francesco Cognetti
• 关键词：Young women ; Breast cancer ; Prognosis ; Estrogen receptor status
• 刊名：The Breast
• 出版年：2006
• 出版时间：April 2006
• 年：2006
• 卷：15
• 期：2
• 页码：269-272
• 全文大小：129 K

文摘

Recent evidence suggests that young women with estrogen receptor (ER)-positive breast cancer (BC) require additional treatment because of the inadequacy of cyclophosphamide, methotrexate fluorouracil (CMF) alone. Herein we report our findings from 368 premenopausal patients given adjuvant anthracycline alone. Overall, patients had a significantly increasing risk of relapse and dying with decreasing age at diagnosis and ER-negative disease. Interestingly, ER expression was not a negative prognostic factor, even among women <35 years, the 5-year disease-free survival (DFS) tending to be higher in patients with ER-positive rather than -negative BC. The potential of combining anthracyclines and endocrine therapies is reviewed and discussed.